COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
It is our pleasure to announce that in honour of the late Mitchell Baran, the founder and leader of the Trudell Medical Group of Companies, the City of London has renamed the portion of Third Street that two of the Trudell Companies are located to “Baransway Drive”.
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
May 1, 2018: Today is the 20th annual World Asthma Day, an event held each May to raise awareness of Asthma worldwide. World Asthma Day is organized by the Global Initiative for Asthma, or GINA (www.ginasthma.org), a World Health Organization collaborative and 501(c)3 organization founded in 1993.
Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2